Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effects of adenosine receptor agonists and antagonists in a genetic animalmodel of primary paroxysmal dystonia
Autore:
Richter, A; Hamann, M;
Indirizzi:
Hannover Sch Vet Med, Dept Pharmacol Toxicol & Pharm, D-30559 Hannover, Germany Hannover Sch Vet Med Hannover Germany D-30559 D-30559 Hannover, Germany
Titolo Testata:
BRITISH JOURNAL OF PHARMACOLOGY
fascicolo: 2, volume: 134, anno: 2001,
pagine: 343 - 352
SICI:
0007-1188(200109)134:2<343:EOARAA>2.0.ZU;2-G
Fonte:
ISI
Lingua:
ENG
Soggetto:
STRIATAL DOPAMINE RELEASE; MUTANT HAMSTER MODEL; BASAL GANGLIA; PHARMACOLOGICAL MANIPULATION; GABAERGIC NEUROTRANSMISSION; RODENT MODEL; D-1; CHOREOATHETOSIS; PATHOPHYSIOLOGY; CLASSIFICATION;
Keywords:
adenosine; choreoathetosis; dystonia; dyskinesia; movement disorders; basal ganglia;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
39
Recensione:
Indirizzi per estratti:
Indirizzo: Richter, A Hannover Sch Vet Med, Dept Pharmacol Toxicol & Pharm, Bunteweg 17, D-30559Hannover, Germany Hannover Sch Vet Med Bunteweg 17 Hannover Germany D-30559 many
Citazione:
A. Richter e M. Hamann, "Effects of adenosine receptor agonists and antagonists in a genetic animalmodel of primary paroxysmal dystonia", BR J PHARM, 134(2), 2001, pp. 343-352

Abstract

1 Recent studies have shown beneficial effects of an adenosine A(2A) receptor agonist in dt(sz) mutant hamsters, an animal model of paroxysmal dystonia, in which stress and consumption of coffee can precipitate dystonic attacks. This prompted us to examine the effects of adenosine receptor agonistsand antagonists on severity of dystonia in dt(sz) hamsters in more detail.2 The non-selective adenosine A(1)/A(2A) receptor antagonists, caffeine (10-20 mg kg(-1) i.p.) and theophylline (10-30 mg kg(-1) s.c.), worsened the dystonia in dt(sz) hamsters.3 Aggravation of dystonia was also caused by the selective adenosine A(1)A(2A) antagonist CGS 15943 (9-chloro2-2-furyl)[1,2,4]triazolo[1,5-c]quinazolin-5-amine) at a dose of 30 mg kg(-1) i.p. and by the adenosine A(1) antagonist DPCPX (8-cyclopentyl-1,3-dipropylxanthine; 20-30 mg kg(-1) i.p.), while the A(2) antagonist DMPX (3,7-dimethyl-1-propargylxanthine; 2 - 4 mg kg(-1) i.p.) and the highly selective A(2A) antagonist ZM 241385 (4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol; 2 - 5 mg kg(-1) i.p.) failed to exert any effects on dystonia.4 In contrast to the antagonists, both the adenosine A(1) receptor agonistCPA (N-6-cyclopentyladenosine; 0.1 - 1.0 mg kg(-1) i.p.) and the A(2A) agonist CGS 21680 (2p-(2carboxyethylphen-ethylamino-5 ' -N-ethylcarboxamindoadenosine; 0.1 - 2.0 mg kg(-1), i.p.) exerted a striking improvement of dystonia.5 These data suggest that the precipitating effects of methylxanthines are, at least in part, related to their adenosine receptor antagonistic action.6 Although adenosine receptor agonists can be regarded as interesting candidates for the therapy of paroxysmal dystonia, adverse effects may limit the therapeutic potential of adenosine A(1) agonists, while beneficial effects of the adenosine A(2A) agonist CGS 21680 were already found at well tolerated doses.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 24/01/20 alle ore 15:16:53